$22.28
Today
as of Sep 4, 16:48 ET
Last 30 days
Recent Press Releases & News
Denali Therapeutics Insider Sold Shares Worth $261,929, According to a Recent SEC Filing
B. Riley Adjusts Denali Therapeutics Price Target to $35 From $30, Maintains Buy Rating
DNLI Stock Gains 33.1% in Three Months: Buy, Sell or Hold the Stock?
Overview
52-week range
$13
$27
66% of range
Avg surprise (last 3)
-0.6%
Avg reaction (last 2)
-8.0%
0% positive
Latest IV / EM
31%
EM ±5.0% · $23 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.68 | — | — | — | — | financials |
| Thu May 7, 2026 | Mar/2026 | $-0.69 | $-0.73 | +5.5% | +11.5% | -3.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.74 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.72 | $-0.74 | +2.7% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.78 | $-0.71 | -9.9% | — | -12.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.63 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.59 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.68 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.72 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $1.30 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.80 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | — | — | — | $0 | — | — | $0 |
| Cost of revenue | $93,000 | — | — | — | $0 | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-131M | $-137M | — | $-137M | $-135M | $-146M | — | $-123M |
| Net income | $-128M | $-128M | — | $-127M | $-124M | $-133M | — | $-107M |
| EPS (diluted) | $-0.68 | $-0.69 | — | $-0.74 | $-0.72 | $-0.78 | — | $-0.63 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $202M | $388M | $205M | $91M | $141M | $57M | $175M | $91M |
| Inventory | $4M | — | $0 | — | — | — | — | — |
| Total current assets | $754M | $1.02B | $901M | $883M | $935M | $879M | $864M | $869M |
| Total assets | $1.16B | $1.27B | $1.14B | $1.06B | $1.17B | $1.27B | $1.37B | $1.45B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $323M | $340M | $131M | $129M | $139M | $149M | $144M | $136M |
| Total equity | $835M | $926M | $1.01B | $926M | $1.03B | $1.12B | $1.23B | $1.32B |